The largest database of trusted experimental protocols

Cilostazol

Cilostazol is a quinolinone derivative with antiplatelet, vasodilatory, and antiproliferative properties.
It inhibits phosphodiesterase III, leading to increased cyclic AMP levels in platelets and vascular smooth muscle cells.
Cilostazol has been used to treat intermittent claudication and prevent thrombosis in patients with peripheral artery disease.
Reseachers can optimize Cilostazol studies using PubCompare.ai, an AI-driven platform that identifies the best protocols from literature, preprints, and patents to generate reproducible, accruate findings and unleash the power of AI-assisted research optimization.

Most cited protocols related to «Cilostazol»

Patients who had intermittent claudication secondary to vascular insufficiency were included if they met the following criteria: (a) a history of any type of exertional leg pain, (b) ambulation during a graded treadmill test limited by leg pain consistent with intermittent claudication,17 (link) and (c) an ankle-brachial index (ABI) ≤ 0.90 at rest4 (link) or an ABI ≤ 0.73 after exercise.18 (link) Patients were excluded for the following conditions: (a) absence of PAD (ABI > 0.90 at rest and ABI > 0.73 after exercise), (b) inability to obtain an ABI measure due to non-compressible vessels, (c) asymptomatic PAD determined from the medical history and verified during the graded treadmill test, (d) use of cilostazol and pentoxifylline initiated within three months prior to investigation, (e) exercise tolerance limited by factors other than leg pain, and (f) active cancer, renal disease, or liver disease. Patient flow in the study is shown in Figure 1.
Publication 2011
Blood Vessel Cilostazol Exercise Tolerance Hepatobiliary Disorder Indices, Ankle-Brachial Intermittent Claudication Kidney Diseases Malignant Neoplasms Pain Patients Pentoxifylline Treadmill Test
Patients with symptomatic PAD were included in this study if they met the following criteria: (1) a history of ambulatory leg pain; (2) ambulatory leg pain confirmed by treadmill exercise4 (link); and (3) an ABI≤0.908 (link) at rest or ≤0.73 after exercise.9 (link) Patients were excluded for the following conditions: (1) absence of PAD (ABI>0.90 at rest and ABI>0.73 after exercise); (2) noncompressible vessels (ABI≥1.40); (3) asymptomatic PAD; (4) use of medications indicated for the treatment of claudication (cilostazol or pentoxifylline) initiated within 3 months prior to investigation; (5) exercise limited by other diseases or conditions; (6) active cancer; (7) end‐stage renal disease defined as stage 5 chronic kidney disease; (8) abnormal liver function; and (9) failure to complete the baseline run‐in phase within 3 weeks. Patient flow in the study is shown in Figure.
Publication 2014
ABI1 protein, human Blood Vessel Chronic Kidney Diseases Cilostazol Kidney Failure, Chronic Malignant Neoplasms Pain Patients Pentoxifylline Pharmaceutical Preparations

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2019
Cerebrovascular Accident Cilostazol Cognition isosorbide mononitrate Patients Pharmaceutical Preparations physiology Safety Systolic Pressure Tablet
Baseline characteristics were compared using chi square for categorical variables and one-way ANOVA for continuous variables. The primary endpoint was assessed using sequential pairwise analysis of covariance adjusting for clinical site, baseline PWT, and cilostazol use (adjustments done to increase precision of the statistical comparison). The second baseline treadmill test was used for the comparison. Separate pairwise models were fit using the given two groups being compared. First, supervised exercise and stenting were each compared with optimal medical therapy with a one-sided 0.025 level of significance. Given significance of both comparisons, supervised exercise and stenting were then compared with a 2-sided 0.05 level of significance.
The secondary endpoints of change in free-living daily step activity measured by pedometer use, biomarkers, and quality of life indicators were assessed by pairwise analysis of covariance, adjusting for baseline cilostazol use and study center but with a two-sided significance level of 0.05 for each comparison without adjustment for multiple comparisons. Pedometer activity was normalized to steps per hour to account for differences in hours of pedometer use during the assessment period. All analyses were conducted according to intention-to-treat. Results are based on available data. Multiple imputation of missing primary endpoint data was also performed.
We estimated the PWT would improve by 60% in OMC, 125% in SE, and 164% for ST, based on published data (7 (link);9 (link);30 (link)). Given baseline mean (SD) PWT estimate of 5.0 (3.8) minutes, with 63 evaluable participants in both the ST and SE groups, or 158 participants total between ST, SE, and OMC, the study had 80% power to detect the difference between SE and ST, >99% power for ST vs. OMC comparison, and 98% power for SE vs. OMC. Allowing for 30% premature withdrawal and inclusion of an exploratory arm of ST plus SE, a sample size of 252 was planned. The sample size was adjusted to 217 after removal of the ST plus SE arm due to slow enrollment. Although the study did not meet conservative pre-specified stopping rules, recruitment was stopped early on recommendations of the DSMB due to slow enrollment after review of interim results.
Publication 2011
Biological Markers Cilostazol neuro-oncological ventral antigen 2, human Premature Birth Therapeutics Treadmill Test
This study evaluated distinct strategies of care in three treatment groups: (i) optimal medical care (OMC), (ii) supervised exercise rehabilitation (SE), and (iii) stent revascularization (ST). A fourth treatment group that combined ST and SE was dropped after enrolling 8 participants upon the recommendation of the Data Safety and Monitoring Board (DSMB) in order to enhance enrollment in treatment groups that were part of the primary endpoint. Randomization was performed using a real-time web-based randomization system in a 2:2:1 ratio (ST:SE:OMC) (half as many enrolled in OMC because the treatment effect between the other groups and OMC was assumed to be much larger than between SE and ST). Randomization was stratified by geographic region and cilostazol use at baseline.
Optimal medical care was established via active promotion of the standards established by the intersocietal 2005 ACC-AHA Guidelines for the Management of Patients with Peripheral Artery Disease in order to promote best practices for risk factor management; use of antiplatelet therapy; and use of claudication pharmacotherapy. All study participants received cilostazol (Pletal™, Otsuka America, Inc., San Francisco, CA) 100 mg by mouth twice daily as tolerated. In addition, OMC included advice about the use of home exercise and diet in the form of standardized verbal instructions as well as printed material (Krames Staywell, San Bruno, CA). Cardiovascular risk factor data were collected and feedback provided to the sites by a central risk factor committee. Risk factors were then managed directly by the local study site.
Supervised exercise consisted of 26 weeks of exercise, three times a week, for an hour at a time. Sites were trained to provide SE using a common protocol and progress of each participant was monitored by an oversight committee (23 (link)).
Stent revascularization was done to relieve all hemodynamically significant stenoses (>50% by diameter) in the aorta and iliac arteries using FDA-approved self-expanding or balloon-expandable stents. The protocol allowed for femoropopliteal endovascular revascularization to treat any additional focal lesions, but this was not done for any study participant. Intra- or post-procedure oral antiplatelet medication use was at the discretion of the operator.
Publication 2011
Antiplatelet Agents Aorta Cilostazol Clinical Trials Data Monitoring Committees Diet Iliac Artery Oral Cavity Patients Peripheral Arterial Diseases Pharmacotherapy Pletal Stenosis Stents Therapeutics Therapies, Exercise

Most recents protocols related to «Cilostazol»

Routine analyses were obtained on admission before coronary angiography and before full medical therapy was started. Before PCI, all patients were administered loading doses of aspirin 200–300 mg and clopidogrel 300–600 mg; alternatively, ticagrelor 180 mg or prasugrel 60 mg was administered. PCI was performed via the femoral or radial approach after an intravenous bolus dose of heparin (50–100 U/kg) to achieve an activated clotting time of > 250 s. DAPT (a combination of aspirin 100 mg/day with clopidogrel 75 mg/day or ticagrelor 90 mg twice daily or prasugrel 5–10 mg/day) was recommended for > 12 months for patients who underwent PCI. Triple antiplatelet therapy (TAPT: cilostazol 100 mg twice daily in addition to DAPT) was left to the discretion of the individual operators. To stabilize glycemic control in the emergency setting, all patients underwent continuous insulin infusion: the infusion lasted until a stable glycemic goal (140–180 mg/dl) for at least 24 h. After that glycemic goal was maintained for 24 h, the infusion was stopped, and subcutaneous insulin was initiated. After discharge from the hospital, all patients were managed and followed for 12 months after PCI, as outpatients, to maintain an HbA1c level at < 7%. Diagnostic coronary angiography and PCI were performed using standard guidelines [2 (link)]. A successful PCI was defined as residual stenosis of < 30% and more than grade 3 flow in Thrombolysis In Myocardial Infarction flow for the infarct-related artery (IRA) after the procedure.
Full text: Click here
Publication 2023
1,2-dilinolenoyl-3-(4-aminobutyryl)propane-1,2,3-triol Arteries Aspirin Cilostazol Clopidogrel Coronary Angiography Diagnosis Emergencies Femur Fibrinolytic Agents Glycemic Control Heparin Infarction Insulin Myocardial Infarction Outpatients Patient Discharge Patients Prasugrel Stenosis Therapeutics Ticagrelor Tyr(TMA)

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
1,2-dilinolenoyl-3-(4-aminobutyryl)propane-1,2,3-triol Antiplatelet Agents Aspirin Aspirin, Dipyridamole Drug Combination Care, Ambulatory Cilostazol Clopidogrel Diagnosis Dipyridamole Hospitalization MAPT protein, human Myocardial Infarction Patients Prasugrel Ticagrelor Ticlopidine
All subjects will take a loading dose of 300 mg clopidogrel or 180 mg ticagrelor plus 300 mg aspirin within 24 h before intervention. After the index procedure, a daily dose of a P2Y12 inhibitor (75 mg clopidogrel per day or 180 mg ticagrelor twice a day) as well as 100 mg aspirin per day will be administered over 12 months after the index procedure (observational period). Aspirin can be replaced by cilostazol (50 mg twice a day) or indobufen (100 mg twice a day) if subjects have a history of a gastric ulcer or bleeding. For the subjects who are eligible for randomization at 12 months (± 1 month), the prerandomization daily dose of the P2Y12 inhibitor will be continued or discontinued based on the randomization arm. Aspirin will be maintained for the duration of treatment. Subjects who switch from one type of P2Y12 inhibitor to another are eligible for enrollment if they have not changed within 6 months before randomization. All drugs will be prescribed to subjects routinely at the outpatient department of each center. Regular records of drug usage will be made throughout the entire study by investigators. Compliance will be reviewed by phone calls to subjects every 3 months from physicians to reconfirm the daily dose of each drug. Prasugrel has not yet been approved for the treatment of coronary artery disease in China.
All XINSORB BRS-treated subjects who are receiving 12 months (± 1 month) of the DAPT post index procedure and who are event-free (from death, MI, stroke, repeat revascularization, scaffold thrombosis, and BARC type 3 or 5 bleeding events) and who are compliant with DAPT (defined as no interruption more than 14 days) are eligible for randomization. The subjects will be randomized at a 1:1 ratio to receive either aspirin alone or a continuation of DAPT for an additional 24 months.
Full text: Click here
Publication 2023
1,2-dilinolenoyl-3-(4-aminobutyryl)propane-1,2,3-triol A 300 Aspirin Cerebrovascular Accident Cilostazol Clopidogrel Coronary Artery Disease indobufen Outpatients Pharmaceutical Preparations Physicians Prasugrel Thrombosis Ticagrelor Ulcer, Gastric
We collected the following patients’ information: age, sex, independent or not before stroke onset, past medical history (e.g., hypertension, diabetes mellitus, and stroke), smoking habit, neurological findings on admission (e.g., Glasgow coma scale [GCS], hemiparesis, dysarthria, facial weakness, and National Institutes of Health Stroke Scale [NIHSS]), subtypes of ischemic stroke based on the TOAST classification (large-artery atherosclerosis [LA], cardioembolism [CE], small-vessel occlusion [SV], stroke of other determined etiology, two or more causes identified, or negative evaluation) [17 (link)], the location of the lesion (supratentorial, infratentorial), complication of urinary tract infection (UTI), prescription at discharge (e.g., cilostazol and angiotensin-converting enzyme inhibitor [ACE-I]), outcome at discharge (e.g., duration of admission and modified Rankin scale [mRS]), and meal at discharge (e.g., normal meal, soft meal, tube feeding, or intravenous hyperalimentation). We considered mRS 0–2 and 3–6 as good and poor outcomes at discharge, respectively. No patients received t-PA and endovascular treatment.
We calculated the integer-based pneumonia risk (ISAN) score, which was a prognostic score for PSP, and assessed by age (<60, 60–69, 70–79, 80–89, and >90 years as 0, 3, 4, 6, and 8 points, respectively), sex (female, 0; male, 2 points), NIHSS score on admission (0–4, 5–15, 16–20, and >21 as 0, 4, 8, and 10 points, respectively), and pre-independence (independent, 0; not independent, 2 points) [10 (link)]. Based on the total ISAN score, the risk of PSP was classified into the following four groups: 0–5, 6–10, 11–14, and >15 points as low-, medium-, high-, and very high-risk groups, respectively [10 (link)].
Full text: Click here
Publication 2023
Angiotensin-Converting Enzyme Inhibitors Arteries Atherosclerosis Blood Vessel Cerebrovascular Accident Cilostazol Dental Occlusion Diabetes Mellitus Dysarthria Facial Paresis Hemiparesis High Blood Pressures Intravenous Hyperalimentation Males Patient Discharge Patients Pneumonia Population at Risk Stroke, Ischemic Urinary Tract Infection Woman
Stock solutions of 20 mg/mL cilostazol (Otsuka Pharmaceutical) were prepared in dimethyl sulfoxide (DMSO, Sigma). Working solutions were freshly prepared by diluting the stock solutions with aerated egg water. The vehicle control contained DMSO at 0.18%. Embryos were placed into these working solutions and cultured at a density of about 30 individuals per 10 ml in a glass beaker. For heart beat measurements, cortisol enzyme-linked immunosorbent assay (ELISA) and whole-mount 3-β-Hydroxysteroid dehydrogenase /Δ5–4 isomerase (3β-Hsd) enzymatic activity assays, the cilostazol treatments commenced immediately after the completion of gastrulation (10 hpf). For the tail fin amputation experiments, the cilostazol treatments were started at 1 day post-fertilization (dpf).
Full text: Click here
Publication 2023
Amputation Cilostazol Embryo Enzyme-Linked Immunosorbent Assay Enzyme Assays Fertilization Gastrulation Hydrocortisone Hydroxysteroid Dehydrogenases Isomerase Pharmaceutical Preparations Pulse Rate Sulfoxide, Dimethyl Tail

Top products related to «Cilostazol»

Sourced in United States, Germany
Cilostazol is a laboratory equipment product manufactured by Merck Group. It is a phosphodiesterase III inhibitor used for various research and analytical applications.
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
Sourced in United States
The Aβ1–42 peptide is a synthetic peptide that corresponds to the first 42 amino acids of the amyloid-beta (Aβ) protein. It is commonly used in research related to Alzheimer's disease and other neurodegenerative disorders.
Sourced in United States, Germany, United Kingdom, France, Sao Tome and Principe, Canada, Italy, Japan, China, Switzerland, Macao, Australia
Forskolin is a lab equipment product manufactured by Merck Group. It is a compound derived from the roots of the Coleus forskohlii plant. Forskolin is used as a tool for research purposes in the laboratory setting.
Sourced in United States, Germany, Italy, Sao Tome and Principe, France, China, Canada, Spain, United Kingdom, Poland, Japan, India, Macao, Argentina
Resveratrol is a naturally occurring polyphenolic compound found in various plants, including grapes and berries. It is commonly used as a dietary supplement and in laboratory research settings. Resveratrol has been studied for its potential antioxidant and anti-inflammatory properties, but its specific functions and applications should be evaluated based on scientific evidence.
Cilostazol is a laboratory chemical used for research purposes. It is a phosphodiesterase type 3 (PDE3) inhibitor that can be used in the study of cardiovascular and platelet function.
Sourced in Germany, United States, Italy, United Kingdom, France, Spain, China, Poland, India, Switzerland, Sao Tome and Principe, Belgium, Australia, Canada, Ireland, Macao, Hungary, Czechia, Netherlands, Portugal, Brazil, Singapore, Austria, Mexico, Chile, Sweden, Bulgaria, Denmark, Malaysia, Norway, New Zealand, Japan, Romania, Finland, Indonesia
Formic acid is a colorless, pungent-smelling liquid chemical compound. It is the simplest carboxylic acid, with the chemical formula HCOOH. Formic acid is widely used in various industrial and laboratory applications.
Sourced in United States, Germany, China, United Kingdom, Canada, Macao, Italy, Japan, France
BAY11-7082 is a laboratory compound that inhibits the activation of the NF-κB transcription factor. It is commonly used in research settings to study the role of NF-κB signaling in various biological processes.
Sourced in United States
DNMDP is a laboratory instrument used for the analysis and characterization of chemical compounds. It is designed to perform nuclear magnetic resonance (NMR) spectroscopy, a widely used analytical technique in various scientific fields. The core function of DNMDP is to detect and measure the magnetic properties of atomic nuclei within a sample, providing information about the chemical structure and composition of the analyzed material.

More about "Cilostazol"

Cilostazol is a quinolinone derivative with potent antiplatelet, vasodilatory, and antiproliferative properties.
It works by inhibiting phosphodiesterase III, leading to increased cyclic AMP levels in platelets and vascular smooth muscle cells.
This mechanism of action contributes to its therapeutic benefits in the management of intermittent claudication and thrombosis prevention in patients with peripheral artery disease.
Researchers can optimize their Cilostazol studies using PubCompare.ai, an AI-driven platform that identifies the best protocols from the available literature, preprints, and patents.
This allows researchers to generate reproducible and acculate findings, unlocking the power of AI-assisted research optimization.
In addition to Cilostazol, other compounds like DMSO (dimethyl sulfoxide), DMEM (Dulbecco's Modified Eagle Medium), Aβ1–42 peptide, Forskolin, Resveratrol, Formic acid, BAY11-7082, and DNMDP may also be relevant in various research contexts.
Researchers can leverage the insights and capabilities of PubCompare.ai to explore the optimal use of these substances and streamline their experimental designs.